Who are Aflibercept (Eylea)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aflibercept Intravitreous Injection, Intravitreal Aflibercept Injection, Eylea® (Aflibercept), VEGF Trap-Eye (BAY86-5321).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aflibercept-eylea.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Aflibercept (Eylea) — Competitive Intelligence Brief

Aflibercept (Eylea) (Aflibercept (Eylea)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor / Soluble decoy receptor. Area: Ophthalmology.

marketed VEGF inhibitor / Soluble decoy receptor VEGF-A, VEGF-B, PlGF (Placental Growth Factor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Aflibercept (Eylea) (Aflibercept (Eylea)) — Ahmad Zeeshan Jamil. Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aflibercept (Eylea) TARGET	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept Intravitreous Injection	Aflibercept Intravitreous Injection	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (placental growth factor)
Intravitreal Aflibercept Injection	Intravitreal Aflibercept Injection	Ophthalmic Consultants of Boston	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Eylea® (Aflibercept)	Eylea® (Aflibercept)	Alvotech Swiss AG	phase 3	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
VEGF Trap-Eye (BAY86-5321)	VEGF Trap-Eye (BAY86-5321)	Bayer	phase 3	VEGF inhibitor / Soluble decoy receptor	VEGF (vascular endothelial growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor / Soluble decoy receptor class)

Ahmad Zeeshan Jamil · 1 drug in this class
Alvotech Swiss AG · 1 drug in this class
Bayer · 1 drug in this class
Ophthalmic Consultants of Boston · 1 drug in this class
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aflibercept (Eylea) — Competitive Intelligence Brief. https://druglandscape.com/ci/aflibercept-eylea. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab